TCTN2

Across TCGA pan-cancer cohorts, TCTN2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TCTN2 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TCTN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TCTN2 expression acts as an unfavorable survival marker.

LUAD, LSCC, and OV are the cancer types where TCTN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.235	0.784	.024	8	view →
LSCC	DFS	Median	All	0.885	1.000	.004	5	view →
OV	DFS	Median	All	0.596	0.884	.018	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TCTN2–LUAD (DFS)

Open the LUAD breakdown →